SARS-cov-2-neutralizing antibody
Single-domain VHH antibodies targeting specific epitopes in the SARS-CoV-2 spike protein address the limited efficacy of existing antibodies by offering broad neutralization against SARS-CoV-2 strains, including mutants, enhancing therapeutic options for COVID-19.
Patent Information
- Application Number
- JP2023081056
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-16
- Publication Date
- 2024-11-28
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing neutralizing antibodies for SARS-CoV-2 have limited cross-reactivity and efficacy against mutant strains, particularly the Omicron variant, necessitating the development of antibodies that can effectively bind and neutralize a wide range of SARS-CoV-2 strains, including future mutants.
Development of single-domain antibodies, specifically VHH antibodies, that target epitopes within the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, including regions from amino acids 33rd tyrosine to 43rd cysteine and 124th aspartic acid to 137th leucine, and from 51st tyrosine to 56th phenylalanine and 178th glycine to 194th valine, exhibiting broad binding and neutralizing activities.
The VHH antibodies demonstrate strong binding and neutralizing capabilities against various SARS-CoV-2 strains, including mutants, providing effective therapeutic agents for COVID-19 prevention and treatment.
Smart Images

Figure 2024165150000009 
Figure 2024165150000010 
Figure 2024165150000011
Abstract
Description
[Technical field]
[0001] The present invention relates to antibodies that neutralize SARS-CoV-2. [Background technology]
[0002] SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) belongs to the betacoronavirus genus, just like SARS-CoV and MERS-CoV, and is a SARS-related coronavirus that causes the novel coronavirus disease (COVID-19). It was first identified in 2019 near Wuhan, Hubei Province, China, and has since caused the global COVID-19 pandemic.
[0003] Like common coronaviruses, SARS-CoV-2 has a large positive-sense RNA genome that encodes four structural proteins, 16 nonstructural proteins (nsp1-16), and several accessory proteins. The structural proteins consist of spike protein, nucleocapsid, membrane protein, and envelope protein, and the spike protein consists of an N-terminal S1 subunit responsible for receptor binding and a C-terminal S2 subunit responsible for membrane fusion. The S1 subunit is further divided into an N-terminal domain (NTD), a receptor binding domain (RBD), subdomain 1 (SD1), and subdomain 2 (SD2). It is known that the S2 subunit is further divided into a fusion peptide (FP), heptad repeat 1 (HR1), and heptad repeat 2 (HR2) (see Non-Patent Document 1).
[0004] Like SARS-CoV, SARS-CoV-2 enters cells by binding to the host cell receptor angiotensin-converting enzyme 2 (ACE2) via its spike protein. Binding to the receptor triggers a conformational change in the spike protein, changing it to an activated state. The activated spike is cleaved at the S1 / S2 site by a protease (TMPRSS2 in SARS-CoV and SARS-CoV-2), releasing the S1 subunit and exposing the FP on the S2 subunit. It is known that the FP is inserted into the target cell membrane, where HR1 and HR2 refold to form a post-fusion conformation, promoting viral membrane fusion with the target cell (see Non-Patent Document 2).
[0005] Structural analysis of the SARS-CoV-2 spike RBD and full-length human ACE2 and the prefusion conformation of the SARS-CoV-2 trimer spike by cryo-electron microscopy and crystallography has progressed, providing insight into the binding mode to ACE2, key mutations on the RBD that form stronger contacts with human ACE2, and epitope insights for identifying cross-reactive antibodies targeting the RBD of SARS-CoV and SARS-CoV-2. Furthermore, glycan analysis of the SARS-CoV-2 spike protein has revealed that the SARS-CoV-2 spike protein has many glycosylation sites, similar to SARS-CoV, and among them, unique glycosylation sites that are not found in SARS-CoV have also been reported, and it has been reported that such unique glycans may promote immune evasion through epitope masking (see Non-Patent Document 3).
[0006] The spike protein of SARS-CoV-2 plays an essential role in viral entry into host cells and is the primary target of neutralizing antibodies. Due to the functionality and high immunogenicity of the coronavirus S1 subunit, most neutralizing antibodies characterized against coronaviruses to date have been reported to target the S1 subunit, especially the RBD. Also, several neutralizing antibodies were developed during previous SARS and MERS epidemics, proving their potential use in treating coronavirus infections. However, many known neutralizing antibodies specific to SARS-CoV RBD (S230, m396, 80R, etc.) do not bind to SARS-CoV-2 even at concentrations up to 1 μM, while it has been reported that none of the monoclonal antibodies isolated from SARS-CoV-2 infected individuals by single B cell selection show cross-reactivity with SARS-CoV RBD. Thus, although many existing neutralizing antibodies have poor cross-reactivity, it has also been reported that there are IgG antibodies such as 47D11 and S309 that show neutralizing activity against both SARS-CoV and SARS-CoV-2, and single domain antibodies such as VHH-72-Fc (see Non-Patent Document 3). To date, neutralizing antibody drugs targeting the spike protein of SARS-CoV-2 have been approved in various countries around the world.
[0007] As of February 2023, more than three years after its outbreak, COVID-19 has not yet been fully contained, and one of the reasons for this is the emergence of SARS-CoV-2 mutant strains. SARS-CoV-2 mutant strains have various mutations (amino acid substitutions, deletions, or insertions) in the amino acid sequence of the spike protein, and changes in infectivity and antigenicity have been confirmed compared to conventional virus strains. The National Institute of Infectious Diseases analyzes the risk of such SARS-CoV-2 mutations and, depending on the evaluation, defines mutant strains as "variants of concern (VOC)" and "variants of interest (VOI)". To date, SARS-CoV-2 mutant strains have appeared all over the world, and currently, the Omicron strain, one of the VOCs, is spreading as a global epidemic strain. In addition, it has been reported that some approved neutralizing antibody drugs have reduced neutralizing activity against the Omicron strain, one of the VOCs (see Non-Patent Document 4). Therefore, in order to suppress the spread of SARS-CoV-2 mutant strains, it is important to develop neutralizing antibodies that are effective not only against existing mutant strains but also against new mutant strains that may emerge in the future.
[0008] Antibodies in immune responses are known to include immunoglobulin M (hereinafter sometimes abbreviated as "IgM"), which increases in the patient's blood relatively early after the body comes into contact with an antigen due to infection, and IgG, which increases thereafter. Here, while typical Ig is composed of light chains and heavy chains, animals of the camelid family are known to produce heavy chain antibodies that do not contain light chains. In addition, a single domain containing the variable region of a heavy chain antibody is a natural single domain, and functions as an antibody by itself. For this reason, it is called a "single domain antibody" (hereinafter sometimes abbreviated as "VHH"). When a virus's three-dimensional epitope contains, for example, a hole-like structure such as an enzyme pocket or a structural portion of a cleft between domains, conventional IgG cannot bind to such an epitope due to its size. In contrast, the above-mentioned VHH has a molecular weight that is one-tenth that of an IgG antibody, and therefore can bind to epitopes with the above-mentioned structures and can also bind to the surface of virus particles modified with many sugar chains, thereby broadening the range of molecules that can be targeted.
[0009] Furthermore, VHHs have excellent acid resistance and heat resistance, and unlike IgG, they do not need to be produced in cultured cells, but can be produced in microorganisms, etc. Therefore, they have the advantage of being easy to mass-produce and purify. Furthermore, since VHHs are composed of a single-chain peptide, their functions can be easily modified using protein engineering techniques or chemical modification techniques, and they are known to have the characteristic of being easy to prepare antibody-drug conjugates (ADCs). [Prior art documents] [Non-patent literature]
[0010] [Non-Patent Document 1] Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol. 2021;28:326. [Non-Patent Document 2] Development of multi-specific humanized llama antibodies blocking SARS-CoV-2 / ACE2 interaction with high affinity and avidity. Emerging Microbes & Infections 2020;9;1034-1036 [Non-Patent Document 3] Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. Cell 2020;181:1004-1015. [Non-Patent Document 4] Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. N Engl J Med. 2022;387:468-470. Summary of the Invention [Problem to be solved by the invention]
[0011] The present invention relates to providing single domain antibodies that exhibit broad binding and neutralizing activity against SARS-CoV-2 and its mutant strains, and methods for using the same. [Means for solving the problem]
[0012] The inventors conducted research to obtain a single-domain antibody that binds to SARS-CoV-2, and succeeded in obtaining a monoclonal antibody that binds to an epitope within the receptor-binding domain of the spike protein, a structural protein of SARS-CoV-2, and exhibits broad neutralizing activity against the virus and its mutant strains.
[0013] That is, the present invention relates to the following 1) to 4). 1) An anti-SARS-CoV-2 monoclonal antibody that binds to the epitope shown in (a) or (b) below. (a) an epitope contained in a region from tyrosine at position 33 to cysteine at position 43 of the amino acid sequence shown in SEQ ID NO: 1 or an amino acid region equivalent thereto, and an epitope contained in a region from aspartic acid at position 124 to leucine at position 137 of the amino acid sequence shown in SEQ ID NO: 1 or an amino acid region equivalent thereto (b) an epitope contained in the amino acid region from tyrosine at position 51 to phenylalanine at position 56 in the amino acid sequence shown in SEQ ID NO:1 or an amino acid region equivalent thereto, and an epitope contained in the region from glycine at position 178 to valine at position 194 in the amino acid sequence shown in SEQ ID NO:1 or a region equivalent thereto 2) A nucleic acid encoding the antibody of 1). 3) A therapeutic agent for SARS-CoV-2 infection, including the antibody of 1). 4) A therapeutic agent for SARS-CoV-2 infection, comprising a combination of an antibody that binds to the epitope shown in (a) and an antibody that binds to the epitope shown in (b). Effect of the Invention
[0014] According to the present invention, it is possible to provide a SARS-CoV-2 antibody that reacts broadly with SARS-CoV-2 and its mutants. The antibody of the present invention has excellent binding activity and neutralizing activity against SARS-CoV-2 and its mutants, and is therefore useful as a therapeutic agent for SARS-CoV-2 infection, i.e., acute respiratory disease (COVID-19). [Brief description of the drawings]
[0015] [Figure 1] Measurement of binding activity of VHH in Corynebacterium tube culture supernatant using biolayer interference method. [Diagram 2] SDS-PAGE image after purification of VHH produced by Bacillus subtilis. [Diagram 3] Measurement of binding activity of His-tagged VM793 by surface plasmon resonance. [Figure 4]Measurement of binding activity of His-tagged VM800 by surface plasmon resonance. [Diagram 5] Measurement of binding activity of VM793 by surface plasmon resonance. [Figure 6] Measurement of VM800 binding activity using surface plasmon resonance. [Figure 7] Measuring the neutralizing activity of VM793 and VM800 against SARS-CoV-2 mutant strains. [Figure 8] Neutralizing activity of VM793·VM800 cocktail against SARS-CoV-2. [Figure 9] Binding site analysis of VM793 to the RBD of SARS-CoV-2 mutant strains by hydrogen / deuterium exchange mass spectrometry. [Figure 10] Binding site analysis of VM800 to the RBD of SARS-CoV-2 mutant strains by hydrogen / deuterium exchange mass spectrometry. [Figure 11] The binding site of VM793 to the RBD of SARS-CoV-2. The amino acid region enclosed in a box contains the binding site. [Figure 12] The binding site of VM800 to the RBD of SARS-CoV-2. The amino acid region enclosed in a box contains the binding site. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] SARS-CoV-2 is a SARS-related coronavirus that causes acute respiratory disease (COVID-19), and its viral genome is a single-stranded positive-strand RNA virus with approximately 29,903 bases. The spike protein, one of the structural proteins of SARS-CoV-2, is composed of an N-terminal S1 subunit responsible for receptor binding and a C-terminal S2 subunit responsible for membrane fusion. The S1 subunit is further divided into an N-terminal domain (NTD), a receptor binding domain (RBD), subdomain 1 (SD1), and subdomain 2 (SD2) (Non-Patent Document 1).
[0017] The anti-SARS-CoV-2 monoclonal antibody of the present invention (hereinafter referred to as the "antibody of the present invention") is an antibody that binds to an epitope present in the receptor binding domain (RBD) of the spike protein, and the epitope is included in the region shown in (a) or (b) below. (a) an epitope contained in the region from tyrosine at position 33 to cysteine at position 43 of the amino acid sequence shown in SEQ ID NO: 1 or a region equivalent thereto, and a region from aspartic acid at position 124 to leucine at position 137 of the amino acid sequence shown in SEQ ID NO: 1 or an amino acid region equivalent thereto (b) an epitope contained in the amino acid region from tyrosine at position 51 to phenylalanine at position 56 of the amino acid sequence shown in SEQ ID NO: 1 or a region equivalent thereto, and a region from glycine at position 178 to valine at position 194 of the amino acid sequence shown in SEQ ID NO: 1 or a region equivalent thereto
[0018] Here, the amino acid sequence shown in SEQ ID NO: 1 refers to the amino acid sequence of the receptor binding domain (RBD) of the spike protein of the SARS-CoV-2 RBD mutant strain (Delta strain). In addition, the term "epitope" refers to an antigenic determinant capable of specific binding to an antibody. The "region corresponding to this" in the above (a) "the region from the 33rd tyrosine to the 43rd cysteine of the amino acid sequence shown in SEQ ID NO: 1 or a region corresponding thereto," "the region from the 124th aspartic acid to the 137th leucine of the amino acid sequence shown in SEQ ID NO: 1 or a region corresponding thereto," and the "amino acid region from the 51st tyrosine to the 56th phenylalanine of the amino acid sequence shown in SEQ ID NO: 1 or a region corresponding thereto," and "the region from the 178th glycine to the 194th valine of the amino acid sequence shown in SEQ ID NO: 1 or a region corresponding thereto" in the above (b) "the region corresponding to this" means, for example, the region corresponding to the relevant region (33rd to 43rd, 124th to 137th, 51st to 56th, 178th to 194th) of the amino acid sequence shown in SEQ ID NO: 1 when alignment with SARS-CoV-2 and its RBD mutant strains is performed using the genetic information processing software GENATYX based on the amino acid sequence of the RBD of the SARS-CoV-2 delta strain (see Figures 11 and 12). The homologous regions are thought to be located in the same region in the three-dimensional structure and are predicted to have similar epitopes on the RBD of SARS-CoV-2.
[0019] The binding ability to the epitope can be evaluated by a method known to those skilled in the art. Specifically, as shown in the Examples described below, it can be evaluated by determining the equilibrium dissociation constant KD by surface plasmon resonance. It can also be evaluated by a method using, for example, ELISA, immunochromatography, isothermal titration calorimetry, biolayer interference, etc.
[0020] Specific examples of antibodies that bind to the epitope shown in (a) above include anti-SARS-CoV-2 antibodies having one or more structural domains including CDR1 consisting of the amino acid sequence shown in GSIFSIYDMG (sequence number 2), CDR2 consisting of the amino acid sequence shown in AISWSGSATY (sequence number 3), and CDR3 consisting of the amino acid sequence shown in RASYQDDLGHNVRDY (sequence number 4). In addition, specific examples of antibodies that bind to the epitope shown in (b) above include anti-SARS-CoV-2 antibodies having one or more structural domains including CDR1 consisting of the amino acid sequence shown in GRTFSTYAVG (sequence number 5), CDR2 consisting of the amino acid sequence shown in DITSGGSTN (sequence number 6), and CDR3 consisting of the amino acid sequence shown in GYKGVWGRSVDY (sequence number 7).
[0021] Here, the CDR (Complementarity Determining Region) includes a sequence-variable antigen recognition site or a random sequence region, and is also called a hypervariable region. In the structural domain of the antibody, the three CDRs are present in the order of CDR1, CDR2, and CDR3 from the N-terminus.
[0022] Even if a mutation is introduced into the CDR consisting of the amino acid sequences shown in SEQ ID NOs: 2 to 7, it is still included in the CDR of the antibody of the present invention as long as it has the ability to bind to SARS-CoV-2.
[0023] The structural domain of the antibody of the present invention may have framework regions on both ends of CDR1, CDR2, and CDR3. The framework region is a region in the variable region of an antibody molecule excluding the complementarity determining regions, and refers to a highly conserved region. That is, one embodiment of the structural domain of the present invention includes a first framework region (FR1), CDR1, a second framework region (FR2), CDR2, a third framework region (FR3), CDR3, and a fourth framework region (FR4) in this order. The amino acid sequences of the framework regions in the structural domains include the following: FR1: the amino acid sequence shown in SEQ ID NO: 8 or an amino acid sequence having 80% or more identity thereto FR2: the amino acid sequence shown in SEQ ID NO: 9 or an amino acid sequence having 80% or more identity thereto, the amino acid sequence shown in SEQ ID NO: 13 or an amino acid sequence having 80% or more identity thereto FR3: the amino acid sequence shown in SEQ ID NO: 10 or an amino acid sequence having 80% or more identity thereto, the amino acid sequence shown in SEQ ID NO: 14 or an amino acid sequence having 80% or more identity thereto FR4: the amino acid sequence shown in SEQ ID NO: 11 or an amino acid sequence having 80% or more identity thereto
[0024] Examples of framework regions consisting of amino acid sequences having 80% or more identity to the amino acid sequences shown in SEQ ID NOs: 8 to 11 and 13 to 14 include framework regions consisting of amino acid sequences having preferably 85% or more, more preferably 90% or more, more preferably 95% or more, more preferably 96% or more, more preferably 97% or more, more preferably 98% or more, and more preferably 99% or more identity.
[0025] Here, the identity of an amino acid sequence refers to the ratio (%) of the number of positions at which identical amino acid residues exist in two amino acid sequences when the two sequences are aligned to the total number of amino acid residues in both sequences. The alignment can be calculated by performing an analysis using the Basic Local Alignment Search Tool (BLAST) of the National Biotechnology Information (NCBI).
[0026] Among the antibodies of the present invention, an antibody having a structural domain (SEQ ID NO: 12) in which FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 are linked in this order, CDR1 is the amino acid sequence shown in SEQ ID NO: 2, CDR2 is the amino acid sequence shown in SEQ ID NO: 3, CDR3 is the amino acid sequence shown in SEQ ID NO: 4, FR1 is the amino acid sequence shown in SEQ ID NO: 8, FR2 is the amino acid sequence shown in SEQ ID NO: 9, FR3 is the amino acid sequence shown in SEQ ID NO: 10, and FR4 is the amino acid sequence shown in SEQ ID NO: 11, is a clone (VM793) highly reactive to SARS-CoV-2 obtained by screening using the cDNA display method in the Examples described below, and is a preferred anti-SARS-CoV-2 antibody. Furthermore, among the antibodies of the present invention, an antibody having a structural domain (SEQ ID NO: 15) in which FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 are linked in this order, CDR1 is the amino acid sequence shown in SEQ ID NO: 5, CDR2 is the amino acid sequence shown in SEQ ID NO: 6, CDR3 is the amino acid sequence shown in SEQ ID NO: 7, FR1 is the amino acid sequence shown in SEQ ID NO: 8, FR2 is the amino acid sequence shown in SEQ ID NO: 13, FR3 is the amino acid sequence shown in SEQ ID NO: 14, and FR4 is the amino acid sequence shown in SEQ ID NO: 11, is a clone (VM800) highly reactive to SARS-CoV-2 obtained by screening using the cDNA display method in the Examples described below, and is a preferred anti-SARS-CoV-2 antibody.
[0027] The form of the antibody of the present invention is not limited as long as it has at least one of the structural domains described above, and it may be a single domain antibody (also called a nanobody) or a multimer (e.g., a dimer) in which at least one of the single domain antibodies is bound. Multimers include multimers in which a plurality of the structural domains of the present invention are linked, as well as multimers in which one or more of the structural domains are linked to other molecules (one or more other structural domains having antigen specificity different from that of the structural domain). A single domain antibody refers to an antibody that has the property of specifically binding to an antigen through a single variable region (antigen-binding domain). Single domain antibodies include antibodies whose variable region consists only of the variable region of a heavy chain (heavy chain single domain antibody) and antibodies whose variable region consists only of the variable region of a light chain (light chain single domain antibody). VHH, which is a heavy chain antibody identified in camelids (e.g., camel, llama, alpaca, etc.), and VNAR, which is a heavy chain antibody derived from cartilaginous fish (e.g., shark), are known as types of single domain antibodies, and VHH is preferred in the present invention. The antibody of the present invention may be humanized. Humanized antibodies can be administered to humans and therefore can be used as pharmaceuticals.
[0028] The method for producing the antibody of the present invention is not particularly limited, and the antibody can be easily produced by known techniques in the art. For example, the antibody can be produced by combining solid-phase peptide synthesis and native chemical ligation (NCL) or by genetic engineering, but a preferred method involves incorporating a nucleic acid encoding the antibody of the present invention into an appropriate vector, introducing the vector into a host cell, and producing the antibody as a recombinant antibody.
[0029] Examples of host cells used in the production of recombinant antibodies include Escherichia coli, Bacillus subtilis, mold, animal cells, plant cells, baculovirus / insect cells, and yeast cells. The expression vector for expressing the antibody can be a vector suitable for various host cells. Examples of expression vectors that can be used include vectors derived from Escherichia coli such as pBR322, pBR325, pUC12, and pUC13; vectors derived from Bacillus subtilis such as pUB110, pTP5, and pC194; shuttle vectors that can be used in common between Escherichia coli and Bacillus subtilis such as pHY300PLK; vectors derived from yeast such as pSH19 and pSH15; bacteriophages such as λ phage; viruses such as adenovirus, adeno-associated virus, lentivirus, vaccinia virus, and baculovirus; and vectors modified from these. These expression vectors have a replication origin, a selection marker, and a promoter suitable for each vector, and may have an enhancer, a transcription termination sequence (terminator), a ribosome binding site, a polyadenylation signal, etc. Furthermore, in order to facilitate purification of the expressed polypeptide, the expression vector may have inserted therein a base sequence for expressing a fused tag such as a FLAG tag, a His tag, an HA tag, or a GST tag.
[0030] When extracting the expressed antibody of the present invention from cultured bacteria or cells, after culturing, the bacteria or cultured cells are collected by a known method, suspended in an appropriate buffer, and the bacteria or cells are disrupted by ultrasonication, lysozyme and / or freeze-thawing, etc., and then a soluble extract is obtained by centrifugation or filtration. The target antibody can be obtained from the obtained extract by appropriately combining known separation and purification methods. Known separation and purification methods include methods that utilize solubility, such as salting out and solvent precipitation; methods that utilize mainly differences in molecular weight, such as dialysis, ultrafiltration, gel filtration, and SDS-PAGE; methods that utilize differences in charge, such as ion exchange chromatography; methods that utilize specific affinity, such as affinity chromatography; methods that utilize differences in hydrophobicity, such as reversed-phase high performance liquid chromatography; and methods that utilize differences in isoelectric point, such as isoelectric focusing.
[0031] Since the antibody of the present invention binds to SARS-CoV-2, by contacting it with a test sample that contains or may contain SARS-CoV-2, it is possible to confirm the presence or absence of SARS-CoV-2 in the sample. Specifically, detection of SARS-CoV-2 using the antibody of the present invention comprises the steps of contacting the antibody of the present invention with a test sample to form a complex between the antibody of the present invention and SARS-CoV-2 in the test sample, and detecting SARS-CoV-2 in the complex. In addition, the antibody of the present invention can also be used as an antibody for detecting virus-specific antibodies in serum, by adding a portion of SARS-CoV-2 antigen to anti-SARS-CoV-2 antibodies (e.g., serum antibodies) contained in an immobilized test sample (serum) to bind the antibodies, and confirming the presence of SARS-CoV-2 antigen in the bound state.
[0032] Test samples include biological samples such as tracheal swabs, nasal swabs, pharyngeal swabs, nasal washings, nasal aspirates, nasal mucus, nasal mucus, saliva, sputum, blood, serum, urine, feces, tissues, cells, tissue or cell fragments, as well as samples collected from solid surfaces on which the virus may be attached, such as doorknobs, toilets, etc. The antibody may or may not be fixed to a solid phase. The step of detecting SARS-CoV-2 in the above-mentioned conjugate can be carried out, for example, by reacting the above-mentioned conjugate with an anti-SARS-CoV-2 antibody that recognizes an epitope different from that of the antibody of the present invention in the conjugate. Alternatively, SARS-CoV-2 in the above-mentioned conjugate may be detected in a liquid phase by a homogeneous assay.
[0033] In addition, the antibody of the present invention can be a component of a kit for detecting SARS-CoV-2. The kit can be used as a diagnostic agent for SARS-CoV-2 infection (COVID-19) and as a tool for developing therapeutic agents for SARS-CoV-2 infection. The detection kit may include, in addition to the anti-SARS-CoV-2 antibody of the present invention, reagents and instruments necessary for detection, such as antibodies, solid phase carriers, buffer solutions, enzyme reaction stopping solutions, microplate readers, etc. In the detection kit, the antibody of the present invention may be immobilized on a solid phase, such as beads, a membrane, the side or bottom surface of a reaction vessel, a plate-like substrate such as a slide glass, or a well substrate such as an immunoplate, to which the antibody of the present invention is directly or indirectly immobilized.
[0034] In addition, the antibody of the present invention binds to the receptor binding domain of the S1 subunit of SARS-CoV-2 and inhibits the virus from infecting cells, i.e., has neutralizing activity. Therefore, the antibody of the present invention can be administered to a mammal and used as a medicine for preventing or treating SARS-CoV-2 infection. When the antibody of the present invention is used as the medicine, it is preferable to use an antibody having one or more structural domains including CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 2, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 3, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 4, preferably an antibody having a structural domain consisting of the amino acid sequence shown in SEQ ID NO: 12 (VM793), and more preferably an antibody having one or more structural domains including CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 5, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 6, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 7, preferably an antibody having a structural domain consisting of the amino acid sequence shown in SEQ ID NO: 15 (VM800) in combination with the antibody having one or more structural domains consisting of CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 5, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 6, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 7, and more ... cocktail. Examples of mammals include humans, mice, rats, hamsters, guinea pigs, rabbits, cats, dogs, monkeys, cows, horses, pigs, etc., with humans being preferred.
[0035] When the antibody of the present invention is used as a pharmaceutical, it may be administered either orally or parenterally, and may be appropriately combined with a known, pharma- ceutically acceptable, non-toxic carrier or diluent. Parenteral administration typically includes injections, but administration by inhalation together with a spray or the like is also possible.
[0036] In such a pharmaceutical composition, the content of the antibody of the present invention in the composition can be appropriately adjusted. In addition, such a medicine can be applied by administering an effective amount of the antibody of the present invention to a subject, such as a patient, who needs to prevent or treat SARS-CoV-2 infection once to several times a week. In this case, the administration method preferably includes intravenous injection, infusion, etc.
[0037] In the present invention, the following aspects are further disclosed in relation to the above-mentioned embodiment. <1> An anti-SARS-CoV-2 monoclonal antibody that binds to the epitope shown in (a) or (b) below. (a) an epitope contained in a region from tyrosine at position 33 to cysteine at position 43 in the amino acid sequence shown in SEQ ID NO: 1 or an amino acid region equivalent thereto, and an epitope contained in a region from aspartic acid at position 124 to leucine at position 137 in the amino acid sequence shown in SEQ ID NO: 1 or an amino acid region equivalent thereto (b) an epitope contained in the amino acid region from tyrosine at position 51 to phenylalanine at position 56 in the amino acid sequence shown in SEQ ID NO:1 or an amino acid region equivalent thereto, and an epitope contained in the region from glycine at position 178 to valine at position 194 in the amino acid sequence shown in SEQ ID NO:1 or a region equivalent thereto <2> The antibody that binds to the epitope represented by (a) has one or more structural domains including CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 2, CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 3, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 4. <1> The antibody described in <3> The antibody that binds to the epitope represented by (b) has one or more structural domains including CDR1 consisting of the amino acid sequence represented by SEQ ID NO:5, CDR2 consisting of the amino acid sequence represented by SEQ ID NO:6, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO:7. <1> The antibody described in <4> a single domain antibody, a single domain antibody multimer comprising at least one such single domain antibody, or an antibody in which at least one such single domain antibody is linked to another molecule; <1> ~ <3> 2. The antibody according to claim 1 , <5> the single domain antibody has a humanized character, <4> The antibody described in <6> <1> ~ <5> A nucleic acid encoding any one of the antibodies. <7> <1> ~ <5> A therapeutic agent for treating SARS-CoV-2 infection, comprising either of the antibodies. <8> A therapeutic agent for SARS-CoV-2 infection comprising a combination of an antibody that binds to the epitope shown in (a) and an antibody that binds to the epitope shown in (b).
[0038] <9> the single domain antibody is a VHH antibody, <4> or <5> The antibody described. <10> The structural domain has, in this order, a first framework region (FR1), a CDR1, a second framework region (FR2), a CDR2, a third framework region (FR3), a CDR3 and a fourth framework region (FR4); <2> or <3> antibodies. <11> FR1 to FR4 are composed of the following amino acid sequences: <10> antibodies. FR1: the amino acid sequence shown in SEQ ID NO: 8 or an amino acid sequence having 80% or more identity thereto FR2: the amino acid sequence shown in SEQ ID NO: 9 or an amino acid sequence having 80% or more identity thereto, the amino acid sequence shown in SEQ ID NO: 13 or an amino acid sequence having 80% or more identity thereto FR3: the amino acid sequence shown in SEQ ID NO: 10 or an amino acid sequence having 80% or more identity thereto, the amino acid sequence shown in SEQ ID NO: 14 or an amino acid sequence having 80% or more identity thereto FR4: the amino acid sequence shown in SEQ ID NO: 11 or an amino acid sequence having 80% or more identity thereto <12> a structural domain (SEQ ID NO: 12) in which FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 are linked in this order, CDR1 is the amino acid sequence shown in SEQ ID NO: 2, CDR2 is the amino acid sequence shown in SEQ ID NO: 3, and CDR3 is the amino acid sequence shown in SEQ ID NO: 4, FR1 is the amino acid sequence shown in SEQ ID NO: 8, FR2 is the amino acid sequence shown in SEQ ID NO: 9, FR3 is the amino acid sequence shown in SEQ ID NO: 10, and FR4 is the amino acid sequence shown in SEQ ID NO: 11; <11> antibodies. <13> a structural domain (SEQ ID NO: 15) in which FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 are linked in this order, CDR1 is the amino acid sequence shown in SEQ ID NO: 5, CDR2 is the amino acid sequence shown in SEQ ID NO: 6, and CDR3 is the amino acid sequence shown in SEQ ID NO: 7, FR1 is the amino acid sequence shown in SEQ ID NO: 8, FR2 is the amino acid sequence shown in SEQ ID NO: 13, FR3 is the amino acid sequence shown in SEQ ID NO: 14, and FR4 is the amino acid sequence shown in SEQ ID NO: 11; <11> antibodies. EXAMPLES
[0039] Example 1: Screening of VHHs 1-1. Screening target molecules The target molecules used were biotinylated SARS-CoV-2 S protein, His, Avitag™, super stable trimer (ACROBiosystems), SARS-CoV2 Spike RBD (L452R, T478K) Fc tag (ACROBiosystems), and biotinylated SARS-CoV-2 Spike RBD, His, Avitag™ (B.1.1.529 / Omicron) (ACROBiosystems).
[0040] 1-2. Synthesis of artificial humanized VHH display cDNA 1-2-(1) Synthesis of mRNA-linker conjugate Humanized artificial VHH sublibrary (Pharmalogical TMUsing a T7 RiboMAX Express Large Scale RNA Production System (Promega) with a DNA library (Epsilon Molecular Engineering) as a template, a transcription reaction was carried out at 37°C for 30 minutes. After the transcription reaction, RQ1 RNase-free DNase (Promega) was added and reacted at 37°C for 15 minutes, and the RNA was purified using RNAclean XP (Beckman Coulter). The RNA concentration was measured using a NanoPad DS-11 (Denovix), and the reagents were mixed so that the final concentrations were 200 mM NaCl, 50 mM Tris-HCl (pH 7.5), 1 μM mRNA, and 1 μM cnvK linker. This mixture was heat-treated using a program of (s1) 90°C, 1 minute, (s2) 70°C, 1 minute, and (s3) 4°C, and then the total energy amount was 406 mJ / cm using a UVP closslinker cl-3000. 2 The mixture was irradiated with UV light at 254 nm until the mRNA-linker conjugate was obtained.
[0041] 1-2-(2) Synthesis of cDNA display molecules After mixing the mRNA-linker conjugates of each sublibrary obtained by the above method, 1.6 mL of cell-free translation solution (Purefrex 1.0) (Gene Frontier) was prepared from 600 μL of the mRNA-linker conjugates and incubated at 37° C. for 30 minutes. Then, 1 M MgCl2 and 3 M KCl were added to a final concentration of 75 mM and 900 mM, respectively, and incubated at 37° C. for 1 hour. Then, 0.5 M EDTA (pH 8.0) was added to a final concentration of 70 mM, and incubated at 4° C. for 5 minutes to obtain an mRNA display solution (total volume 3.2 mL). The obtained mRNA display solution was purified using 1.92 mL of Dynabeads Streptavidin MyOne C1 (Thermo Scientific) according to the attached protocol. A reverse transcription reaction solution consisting of 320 μL of 5xRT Buffer (Nippon GENE), 64 μL of 25 mM dNTPs, 32 μL of Reverse Transcriptase (200 U / mL, Nippon GENE), and 1184 μL of ultrapure water was added to the mRNA display immobilized beads and reacted at 42°C for 1 hour. The reaction product was eluted from the beads with 500 μL of elution buffer containing RNaseT1 (Thermo Fisher Scientific), and then the cDNA display was purified using 400 μL of His-Mag Sepharose (Cytiva) and eluted with 50 μL of His-Mag elution solution to obtain an artificial humanized VHH-presenting cDNA display molecule (cDNA-linker-peptide conjugate).
[0042] 1-3. Screening of anti-SARS-CoV-2 VHH antibodies 1-3-(1) Selection against SARS-CoV-2 S protein 35μL of 200μg / mL biotinylated SARS-CoV-2 S protein, His,Avitagtm, super stable trimer (hereinafter referred to as SAR-S-CoV-2 S trimer) was diluted with 15μL of PBS to prepare a 1μM SARS-CoV2 S trimer solution. 47μL of artificial humanized VHH-presenting cDNA display solution prepared by the above method from the mRNA-linker conjugate 600pmol scale, 0.5μL of 10% Tween 20, and 2.5μL of 5mg / mL Heparin solution were added to 50μL of this solution in that order and incubated at 4℃ for 30 minutes. Next, this cDNA display mixture was added to 120 μL of magnetic beads (Dynabeads Myone streptavidin C1) (Veritas) and mixed by inversion at 4°C for 30 minutes. After removing the supernatant, the magnetic beads were washed three times with PBS-T. After elution, the cDNA display was recovered from the eluate using AMpure XP (Beckman Coulter).
[0043] 1-3-(2) Preparation of anti-SARS-CoV-2 S protein binding DNA library The cDNA display sample obtained above was subjected to PCR. cnvK NewYtag for polyA (sequence number 16) and PL_T7pro (sequence number 17) were used as primers, and PCR was performed using PrimeSTAR Max (Takara Bio) with an annealing temperature of 60°C and an extension reaction of 35 seconds. The obtained PCR product was purified using AMpure XP (Beckman Coulter) according to the product's instructions, and an anti-SARS-CoV-2 S protein binding DNA library was created.
[0044] 1-3-(3) Biotinylation of SARS-CoV-2 RBD delta mutant (L452R, T478K) 100 μL of 5.9 μM SARS-CoV2 Spike RBD (L452R, T478K) Fc tag (ACROBiosystems) solution was mixed with 1 mM biotinylation reagent (EZ-Link TMSulfo-NHS-PEG12-Biotin (Thermo Fisher Scientific, 11.8 μL) was added and reacted at room temperature for 1 hour. TM The Spin Desalting Columns, 7K MWCO, 0.5 mL (Thermo Fisher Scientific) were replaced with PBS according to the instructions, the reaction solution was added, and the column was centrifuged at 1500xg for 2 minutes to replace the buffer in the reaction solution with PBS, remove unreacted biotinylation reagent, and obtain each biotinylated SARS-CoV-2 RBD delta mutant strain.
[0045] 1-3-(4) Anti-SARS-CoV-2 RBD mutant VHH antibody screening (Round 1) Using the anti-SARS-CoV-2 S protein-binding DNA library obtained in 1-3-(2) above as a template, mRNA-linker conjugates were obtained in the same manner as in 1-2-(1) above, and then cDNA display solutions were prepared for the Delta mutant and Omicron mutant strains from 20 μL of the mRNA-linker conjugates in the same manner as in 1-2-(2) above. 50 μL of 500 nM biotinylated SARS-CoV-2 RBD mutant solution, 0.5 μL of 10% Tween, and 2.5 μL of 5 mg / mL Heparin solution were added sequentially to 47 μL of each cDNA display solution diluted with PBS, and incubated at 4 °C for 1 hour. Next, this cDNA display mixture was added to 40 μL of magnetic beads (Dynabeads Myone streptavidin C1) (Veritas), mixed by inversion at 4℃ for 30 minutes, the supernatant was removed, the magnetic beads were washed three times with PBS-T, and after elution, cDNA display was recovered from the eluate using AMpure XP (Beckman Coulter). This recovered sample was subjected to PCR in the same manner as in 3-2 above.
[0046] 1-3-(5) Anti-SARS-CoV-2 RBD mutant VHH antibody screening (rounds 2 and 3) Using the PCR products of each mutant strain obtained in 1-3-(4) above as templates, cDNA display solutions were prepared in the same manner as in 3-4 above. 50 μL of 200 nM biotinylated SARS-CoV-2 RBD mutant solution, 0.5 μL of 10% Tween, and 5 μL of 10 mg / mL BSA solution were added sequentially to 44.5 μL of each cDNA display solution diluted with PBS, and incubated at 4 ° C for 1 hour. Next, this cDNA display mixture was added to 20 μL of magnetic beads (Dynabeads Myone streptavidin C1) (Veritas), mixed by inversion at 4 ° C for 30 minutes, the supernatant was removed, and the magnetic beads were washed three times with PBS-T. After elution, cDNA display was recovered from the eluate using AMpure XP (Beckman Coulter). The recovered cDNA display solution was subjected to PCR amplification, and this procedure was repeated once more to obtain an anti-SARS-CoV-2 RBD mutant (delta-omicron) VHH antibody DNA library.
[0047] (Example 2) Identification of positive clones from anti-SARS-CoV-2 RBD mutant (delta&omicron) VHH antibody DNA library 2-1. Construction of VHH expression plasmid library The DNA library encoding the VHH selected by the above screening was cloned into a plasmid vector for VHH expression. First, a sequence for restriction enzyme treatment was added to the DNA library obtained by screening by PCR to obtain a PCR product. The reaction solution was 25 μL of PrimeSTAR MAX, 1 μL of the screening product, and 10 pmol each of PL_VHH_SfiI-NcoI_FW (SEQ ID NO: 18) and PL_VHH_BamHI-NotI_RV (SEQ ID NO: 19) adjusted to 50 μL with ultrapure water. The PCR program consisted of an annealing temperature of 55° C. and an extension time of 15 seconds, with 25 cycles of PCR reaction. This PCR product and the C. glutamicum expression plasmid vector were treated with the restriction enzyme BamHI at 37° C. for 1 hour, and then treated with the restriction enzyme SfiI at 50° C. for 1 hour. The reaction solution derived from the PCR product that would become the insert DNA was purified using AMPure XP, and the reaction product derived from the plasmid vector was subjected to electrophoresis on a 1% agarose gel at 100V for 30 minutes, followed by excision and purification. The purified plasmid vector DNA was dephosphorylated for 1 hour at 37°C using the dephosphorylation enzyme Fast AP Thermosensitive Alkaline Phosphatase (Thermo Fisher Scientific). The insert DNA and the plasmid vector DNA were then mixed at a molar ratio of 1:10, and ligation was carried out overnight at 16°C using Ligation high (Toyobo), to obtain a plasmid library into which the selected VHH library had been introduced.
[0048] 2-2. Obtaining culture supernatant containing selected VHHs using Corynebacterium tuberculosis Each plasmid library was introduced into Corynebacterium glutamicum by electroporation to obtain a transformant. The obtained transformant was inoculated into CM2G medium and cultured overnight at 30°C. The culture solution was then subcultured into PM1S medium for VHH expression and cultured at 25°C for 72 hours to allow secretion and expression of VHH in the culture supernatant. The culture supernatant was collected by centrifugation at 3000xg, and the bacterial cells were removed from the supernatant by filtering through a 0.22μm filter.
[0049] 2-3. Single point binding assay using biolayer interferometry Using Octet RED384 (Fortebio), the VHH clones produced above were immobilized on a His1K sensor chip to measure the binding activity to each target molecule. The ligands, SARS-CoV-2 Spike RBD (L452R, T478K) and Fc Tag (Acro Biosystems), were adjusted to a concentration of 200 nM, and 70 μL of the measurement solution was added to a 384-well plate to measure the binding of each target molecule. Dip and Read were performed before the measurement. TM The tip of the His1K Biosensor (Fortebio) was immersed in 200 μL of PBS-T (0.05% Tween 20, pH 7.4) for 10 minutes to hydrate the sensor chip. The measurement order conditions for each run were as follows: 1) Baseline step: Measurement in PBS-T for 30 seconds. 2) Loading step: Measurement for 60 seconds using VHH diluted 50-fold with PBS-T. 3) Baseline step: Measurement in PBS-T for 30 seconds. 4) Association step: Measurement for 100 seconds with each target molecule diluted in PBS-T. 5) Dissociation step: Measurement in PBS-T for 100 seconds. 6) Regeneration step: Measurement in Glycine-HCl (pH 2.2) for 5 seconds, then in PBS-T for 30 seconds. This process was repeated three times. The data obtained was processed using Octet software version (1.2.1.5) (Molecular Devices). The analysis results are shown in Figure 1. VM793 and VM800 were selected as positive clones by defining clones that showed a binding response value of 0.1 nm or more.
[0050] 2-4. Analysis of the base sequences encoding positive clones The nucleotide sequence of each VHH gene was identified for the positive clones selected in 2-3. The transformants of each positive clone were cultured overnight at 37°C, and colony PCR was performed on the culture solution. 10 units of Exonuclease I (E. coli) (New England Biolabs) and 0.5 units of Shrimp Alkaline Phosphatase (rSAP) (New England Biolabs) were added to the obtained PCR product, and the product was reacted at 37°C for 45 minutes, and then at 80°C for 15 minutes to inactivate the product. DNA sequence analysis was outsourced to Eurofins genomics using each reaction solution. As a result, it was found that the nucleotide sequences encoding VM793 and VM800 were (SEQ ID NO: 20) and (SEQ ID NO: 21), respectively. It was also found that the amino acid sequences encoding VM793 and VM800 were (SEQ ID NO: 12) and (SEQ ID NO: 15), respectively. In the amino acid sequence, in VM793, 1 to 25 are FR1, 26 to 35 are CDR1, 36 to 49 are FR2, 50 to 59 are CDR2, 60 to 98 are FR3, 99 to 113 are CDR3, and 114 to 124 are FR4; in VM800, 1 to 25 are FR1, 26 to 35 are CDR1, 36 to 49 are FR2, 50 to 58 are CDR2, 59 to 97 are FR3, 98 to 109 are CDR3, and 110 to 120 are FR4.
[0051] Example 3: Production of VM793 and VM800 using protease-deficient recombinant Bacillus subtilis 3-1. Construction of plasmids for expressing VHH The plasmid sequence was amplified by PCR using the recombinant plasmid pHY-S237 (JP Patent Publication 2014-158430) prepared based on pHY300PLK as a template, a primer set of 5'-GATCCCCGGGAATTCCTGTTATAAAAAAAGG-3' (SEQ ID NO: 22) and 5'-ATGATGTTAAGAAAGAAAACAAAGCAG-3' (SEQ ID NO: 23) and PrimeSTAR Max DNA polymerase (TaKaRa). The promoter DNA derived from the spoVG gene was amplified by PCR using the Bacillus subtilis 168 genome as a template and a primer set of 5'-GAATTCCCGGGGATCTAAGAAAAGTGATTCTGGGAGAG-3' (SEQ ID NO: 24) and 5'-CTTTCTTAACATCATAGTAGTTCACCACCTTTTCCC-3' (SEQ ID NO: 25). The obtained promoter DNA was incorporated into a plasmid sequence using the In-Fusion HD Cloning Kit (Takara) to construct a plasmid for expressing VHH linked to the spoVG promoter.
[0052] 3-2. Design of plasmids for producing His-tagged VM793 and VM800 The amino acid sequences were designed as His-tagged VM793 (SEQ ID NO: 27) and His-tagged VM800 (SEQ ID NO: 28) by adding a GS+His tag (SEQ ID NO: 26) to the C-terminus of VH793 (SEQ ID NO: 12) and VM800 (SEQ ID NO: 15). For production in Bacillus subtilis, the His-tagged VH793 nucleotide sequence (SEQ ID NO: 29) and the His-tagged VH800 nucleotide sequence (SEQ ID NO: 30) were synthesized by incorporating them between SEQ ID NO: 31 and SEQ ID NO: 32 of the VHH expression plasmid constructed in 3-1 by GenPlus cloning from Genescript Inc.
[0053] 3-3. Design of plasmids for producing VM793 and VM800 Using the His-tagged VM793 expression plasmid and His-tagged VM800 expression plasmid prepared in 3-2 above as template DNA, a VM793 expression plasmid and a VM800 expression plasmid were prepared, respectively. The VM793 expression plasmid was prepared by amplifying the plasmid sequence by PCR using the His-tagged VM793 expression plasmid as a template and a primer set of 5'-GTGACAGTCTCTTCATAATCTATTAAACTAGTTATAGGGTTATC-3' (SEQ ID NO: 33) and 5'-TGAAGAGACTGTCACCAACG-3' (SEQ ID NO: 34) and PrimeSTAR Max DNA polymerase (TaKaRa), and transforming the obtained PCR product into Bacillus subtilis by the method shown in 3-4. The VM800 expression plasmid was prepared by amplifying the plasmid sequence by PCR using the His-tagged VM800 expression plasmid as a template and a primer set of 5'-GTGACAGTCTCTTCATAATCTATTAAACTAGTTATAGGGTTATC-3' (sequence number 33) and 5'-TGAAGAGACTGTCACCAACG-3' (sequence number 34) with PrimeSTAR Max DNA polymerase (TaKaRa), and then transforming the resulting PCR product into Bacillus subtilis by the method shown in 3-4.
[0054] 3-4. Construction of recombinant Bacillus subtilis A strain lacking extracellular protease genes (epr, wprA, mpr, nprB, bpr, nprE, vpr, aprE, aprX) was prepared from Bacillus subtilis 168 strain (hereinafter referred to as 168 strain) according to the method described in Japanese Patent No. 4485341. In addition, the sigF gene involved in sporulation was deleted from Bacillus subtilis strain Dpr9, which lacks all of the above nine extracellular protease genes, according to the method described in Japanese Patent No. 4336082. The obtained extracellular protease multiple deletion strain is referred to as Dpr9ΔsigF. Introduction of a plasmid or PCR product into Dpr9ΔsigF was performed by the protoplast method described below. 1 mL of glycerol-stocked Dpr9ΔsigF was inoculated into 1 mL of LB liquid medium and cultured overnight at 30 ° C. and 210 rpm with shaking. The next day, 10 μL of this culture was inoculated into a new 1 mL of LB liquid medium and cultured at 37 ° C. and 210 rpm with shaking for about 2 hours. This culture was collected in a 1.5 mL tube and centrifuged at 1,2000 rpm for 5 minutes. The pellet from which the supernatant was removed was suspended in 500 μL of SMMP (0.5 M sucrose, 20 mM disodium maleate, 20 mM magnesium chloride hexahydrate, 35% (w / v) Antibiotic medium 3 (Difco)) containing 4 mg / mL Lysozyme (SIGMA) and incubated at 37 ° C. for 1 hour. The mixture was then centrifuged at 3,500 rpm for 10 minutes, the supernatant was removed, and the pellet was suspended in 400 μL of SMMP. 33 μL of this suspension was mixed with various plasmids, and 100 μL of 40% PEG was added and vortexed. 350 μL of SMMP was added to this solution, mixed by inversion, and shaken at 30°C and 210 rpm for 1 hour. The entire amount was then applied to a DM3 agar medium plate and incubated at 30°C for 2 to 3 days.
[0055] 3-5.VHH production The recombinant Bacillus subtilis prepared in 3-4 was inoculated into 1 mL of LB medium containing 50 ppm tetracycline and shaken at 32°C overnight to prepare a preculture solution. For Dpr9ΔsigF, the preculture solution was inoculated at 1% into 20 mL of 2×L-mal medium placed in a pleated Erlenmeyer flask and cultured at 30°C for 72 hours with shaking. At the end of the culture, 1 mL of the culture solution was centrifuged in a microtube at 4°C, 15,000 rpm for 5 minutes, and the supernatant was collected. Ni-NTA agarose beads (Fujifilm Wako Pure Chemical Industries, Ltd.) were used for His-tagged VHHs, and Amsphere TM Purification was performed using A3 (JSR Life Sciences) according to the kit protocol.
[0056] 2 μL of purified aqueous solution of each VHH (both 1 mg / mL), 5 μL of NuPAGE™ LDS Sample Buffer (4×) (Thermo Fisher Scientific), 2 μL of NuPAGE™ Sample Reducing Agent (10×) (Thermo Fisher Scientific), and 4.11 μL of H2O were mixed and heated at 100°C. Then, 10 μL of the sample solution was applied to the wells of the gel. As a molecular weight marker, 5 μL of Novex™ Sharp Pre-stained Protein Standard (Thermo Fisher Scientific) was also applied to the wells of the gel. The gel used was NuPAGE™ 10%, Bis-Tris, 1.0 mm, Mini Protein Gel, 12-well (Thermo Fisher Scientific). The running buffer used was a buffer prepared by diluting NuPAGE™ MES SDS Running Buffer (20×) (Thermo Fisher Scientific) 20 times with water. The XCell SureLock™ Minicell Electrophoresis System (Thermo Fisher Scientific) was used as the electrophoresis tank, and electrophoresis was performed for 40 minutes at a voltage of 200 V connected to a PowerEase™ 90W Power Supply (Thermo Fisher Scientific). The gel was then stained with GelCode™ Blue Stain Reagent (Thermo Fisher Scientific) to confirm the presence or absence of the target protein band. As a result, it was revealed that all VHHs were produced with high purity (Figure 2).
[0057] Example 4: Evaluation of binding activity of VHH by surface plasmon resonance method 4-1. Evaluation of binding activity of His-tagged VM793 The binding activity of His-tagged VM793 to the Delta and Omicron (B.1.1.529) RBDs was evaluated using Biacore 8K (Cytiva). Avi-tagged Delta RBD [Acrobiosystem, Biotinylated SARS-CoV-2 Spike RBD (L452R, T478K), His, Avitag (trademark) (MALS verified)] and Avi-tagged B.1.1.529 RBD [Biotinylated SARS-CoV-2 Spike RBD, His, Avitag (trademark) (B.1.1.529 / Omicron) (MALS verified)] were immobilized as ligands on a sensor chip (Series S, Sensor Chip CAP) (Cytiva) using the Biotin capture kit, Series S (Cytiva). Then, His-tagged VM793 was run as an analyte, and the binding activity of both was measured in Single-cycle kinetics mode. HBS-EP+ Buffer (Cytiva) was used as the running buffer. The detailed measurement sequence is as follows. First, RBD was immobilized on the sensor chip. The flow rate was set to 2 μL / min, and Biotin CAPture reagent included in the kit was run for 300 seconds. Then, RBD diluted to 0.5 μg / mL with running buffer was run at a flow rate of 2 μL / min for 180 seconds to immobilize it on the sensor chip. Next, binding activity was measured. The flow rate was set to 30 μL / min, and VHH diluted to an appropriate concentration with running buffer was run with Contact Time set to 180 seconds and Dissociation Time set to 600 seconds to measure the interaction between RBD and VHH. Finally, the sensor chip surface was regenerated. The flow rate was set to 10 μL / min, and 350 mM EDTA solution (pH 8.0) was added for 60 seconds to elute the RBD immobilized on the sensor chip. After the measurement, analysis was performed using the 1:1 binding model using Biacore Insight Evaluation Evaluation Software (Cytiva).
[0058] The results are shown in Figure 3 and Table 1. It was revealed that His-tagged VM793 exhibited good binding activity to the RBDs of Delta and B.1.1.529.
[0059] [Table 1]
[0060] 4-2. Evaluation of binding activity of His-tagged VM800 The binding activity of His-tagged VM800 to the RBDs of Delta and Omicron (B.1.1.529) was evaluated according to the method described in 4-1 above. The results are shown in Figure 4 and Table 2, and it was revealed that VM800 showed good binding activity to both RBDs.
[0061] [Table 2]
[0062] 4-3.Evaluation of binding activity of VM793 According to the method of 4-1 above, Wuhan type [Acrobiosystem, Biotinylated SARS-CoV-2 Spike RBD, His, Avitag (trademark) (MALS verified)], Delta type [Acrobiosystem, Biotinylated SARS-CoV-2 Spike RBD (L452R, T478K), His, Avitag (trademark) (MALS verified)], B.1.1.529 type [Biotinylated SARS-CoV-2 Spike RBD, His, Avitag (trademark) B.1.1.529 / Omicron) (MALS verified)], BA.4 / 5 type [Acrobiosystem, Biotinylated SARS-CoV-2 Spike RBD, His, Avitag (trademark) (BA.4&BA.5 / Omicron) (MALS verified)], BA.2.75 type [Acrobiosystem, Biotinylated SARS-CoV-2 Spike The binding activity of VM793 was evaluated against the RBD of each of the mutant strains (RBD, His, Avitag™ (BA.2.75 / Omicron) (MALS verified)). The results are shown in FIG. 5 and Table 3. VM793 showed very good binding activity against all of the mutant strains. In other words, it was revealed that VM793 has a wide range of binding activity against various mutant strains.
[0063] [Table 3]
[0064] 4-4. Evaluation of binding activity of VM800 by surface plasmon resonance method According to the method of 4-1 above, the binding activity of VM800 against the RBD of Wuhan type, Delta type, B.1.1.529 type, BA.4 / 5 type, and BA.2.75 type is evaluated. The results are shown in Figure 6 and Table 4. VM800 showed good binding activity against Wuhan type and Delta type. On the other hand, the binding activity against B.1.1.529 type tended to decrease slightly, and binding to BA.4 / 5 type and BA.2.75 type was not detected.
[0065] [Table 4]
[0066] Example 5: Evaluation of SARS-CoV-2 neutralizing activity of VHHs using cultured cells 5-1. Construction of human ACE2 (Angiotensin-Converting Enzyme 2)-transfected 293T cells Human ACE2 was introduced into 293T cells (ATCC) using a lentiviral vector, and selectively cultured with hygromycin (Nacalai) to stably express human ACE2. The cultured cells thus produced are called 293T / ACE2 cells.
[0067] VM793 and VM800 were used. Each VHH was diluted 3-fold with a maximum concentration of 100 μg / mL or 33.3 μg / mL. VHH of each concentration was dispensed into a U-bottom 96-well plate (Violamo) at 100 μL per well. The virus strains used are shown in Table 5. Each virus strain was adjusted to an MOI (Multiplicity of Infection) of 5 (RNA copies) when infecting cultured cells. 100 μL of each adjusted virus solution was mixed with 100 μL of VHH solution, reacted at 37°C for 2 hours, and then incubated at 4°C for 16 hours.
[0068] [Table 5]
[0069] 293T / ACE2 cells were cultured to 100% confluence, and 100uL of 2% Fetal Bovine Serum (FBS)-containing medium (Dulbecco's modified Eagle's medium; Nacalai) was added per well. 100uL of the virus-VHH mixture was added to the 293T / ACE2 cells and cultured at 37℃ in the presence of 5% CO2 for 48 hours.
[0070] After 48 hours, the viral load (RNA copy number) in the culture supernatant of 293T / ACE2 cells was measured by qPCR. SARS-CoV-2 Detection Kit (Toyobo) was used for quantitative PCR. 3 μL of culture supernatant was mixed with 3 μL of pretreatment solution, and 3 μL of that was added to the RT-PCR reaction solution (15 μL of reaction solution, 2.5 μL of enzyme solution, 2.5 μL of primer-probe solution), and quantitative PCR was performed using a LightCycler (registered trademark) 96. The reaction conditions were reverse transcription reaction at 42°C for 5 minutes, pre-denaturation at 95°C for 10 seconds, and cycle reaction [denaturation at 95°C for 1 second, annealing at 50°C for 3 seconds, and extension at 55°C for 10 seconds] for 45 cycles. Detection was performed.
[0071] Based on the number of SARS-CoV-2 RNA copies in the culture supernatant, the inhibition rate of cell infection by VM793 and VM800 against each SARS-CoV-2 mutant strain (Figure 7) and the 50% inhibitory concentration (IC 50 ) (Tables 6 and 7). As a result, it was confirmed that VM793 exhibited good neutralizing activity against the Delta, BA.1.18, BA.2, BA.5.2.1, and BQ.1 strains. It was also confirmed that VM800 exhibited good neutralizing activity against the Delta and BA.1.18 strains.
[0072] [Table 6]
[0073] [Table 7]
[0074] Example 6: Evaluation of SARS-CoV-2 neutralizing activity of VHH cocktails using cultured cells The neutralizing activity against SARS-CoV-2 when VM793 and VM800 were mixed was evaluated according to the method described in Example 5. The virus strain used was the KUH003 strain, which was confirmed to have neutralizing activity in VM793 and VM800. VM793 and VM800 were mixed in equal amounts after adjusting the concentration of both VHHs to 33 μg / mL, so that the total amount of VHH was 66 μg / mL. The mixture of VM793 and VM800 is called the VM793·VM800 cocktail.
[0075] Based on the number of SARS-CoV-2 RNA copies in the culture supernatant, the inhibition rates of cell infection by each SARS-CoV-2 mutant strain of VM793, VM800, and the VM793·VM800 cocktail (Figure 8) and IC 50 (Table 8) was calculated. As a result, it was confirmed that mixing VM793 and VM800 synergistically improved the inhibition rate of SARS-CoV-2 cell infection.
[0076] [Table 8]
[0077] (Example 7) Binding site analysis of VHH for SARS-CoV-2 RBD To determine the binding sites of VM793 and VM800 in the SARS-CoV-2 RBD mutants (delta strain), hydrogen / deuterium exchange mass spectrometry (HDX-MS) was performed using an automated HDX2 system (LEAP Technologies). SARS-CoV-2 Spike RBD (L452R, T478K), His Tag (MALS verified) (Acro Biosystems) was used as the antigen. The amino acid sequence of the antigen is SEQ ID NO: 36, in which a His tag (SEQ ID NO: 35) is added via a linker to the C-terminus of the amino acid sequence shown in SEQ ID NO: 1. The automated HDX2 system consisted of an ultra-high performance liquid chromatography (Water, nano Acquity UPLC) mass spectrometer (Waters, Synapt XS) and a LEAP PAL (Trajan Automation, NC). The final protein concentration of each evaluation sample was set to 25 μM. Reference and deuterium samples were prepared by diluting 3 μL of each evaluation sample with 57 μL of light water buffer (10 mM potassium phosphate, pH 7.0) and heavy water buffer (10 mM potassium phosphate, pD 7.0), respectively. The deuterium exchange temperature and time were 20°C, and five time points were used: 0.5 min, 1 min, 10 min, 60 min, and 240 min. After dilution, the protein samples were quenched with 50 μL of ice-cold quench buffer (100 mM potassium phosphate, 4 M guanidine hydrochloride, 200 mM TCEP, pH 2.3, 0°C). 90 μL of the quenched sample was injected into the HDX module, and protein digestion was performed on an online pepsin column (Waters Enzymate BEH pepsin) at a flow rate of 70 μL / min for 3 min, after which peptide fragments were trapped on a trap column (Waters, Acquity BEH C18 Vanguard 1.7 μm).The peptides were then purified using an analytical column (Waters, Acquity BEH C18: 1.7 μm) with a 17-minute gradient (5-95% as acetonitrile) of ultrapure water containing 0.1% formic acid, and electrosprayed onto a Waters Synapt XS. The masses of the peptide fragments were detected by setting the mass / charge (m / z) acquisition window to 50-2000. Lock mass correction was performed by intermittent injection of 500 f / mol GluFib (785.8426 m / z, Sigma-Aldrich). MS of SARS-CoV-2 RBD delta strain. E Peptides were identified from the analysis, and the data were analyzed using ProteinLynx Global Server software (Waters). The peptides identified by PLGS were then used in DynamX 3.0 software (Waters). Deuterium uptake for each peptide was calculated by comparing the centroid of the mass envelope of the deuterated and undeuterated samples. HDX data were analyzed by calculating and summing the difference in deuterium uptake for the same peptide between the two states, free and complexed with RBD and VHH, at all HDX time points. No back-exchange correction factor was applied in the HDX data analysis, since the same peptide in both protein states was compared.
[0078] As a result, deuterium uptake by VM793 and SARS-CoV-2 RBD mutants was observed for 124 peptides commonly observed in free and antigen-antibody bound states. Of these, the degree of deuterium exchange was calculated for 48 peptides, covering 95.4% of the peptide sequence of RBD. A significant decrease in deuterium uptake due to VM793 binding was observed in the amino acid region from tyrosine at position 33 to cysteine at position 43 of the amino acid sequence of RBD shown in SEQ ID NO: 1, and in the region from aspartic acid at position 124 to leucine at position 137 (Figure 9). Therefore, it was found that the amino acid sequence in the RBD contains the binding site of VM793. In other words, it was found that VM793 shows a binding site for RBD that is different from that of known SARS-CoV-2 neutralizing antibodies. Deuterium uptake by VM800 and SARS-CoV-2 RBD mutants was observed for 217 peptides commonly observed in free and antigen-antibody bound states. Of these, the degree of deuterium exchange was calculated for 45 peptides, covering 81.4% of RBD peptides. A significant decrease in deuterium uptake due to VM800 binding was observed in the amino acid region from tyrosine at position 51 to phenylalanine at position 56 in the amino acid sequence of RBD shown in SEQ ID NO: 1, and in the region from glycine at position 178 to valine at position 194 (Figure 10). Therefore, it was found that this region in the RBD is the region of the amino acid sequence that contains the binding site of VM800.
[0079] Based on the amino acid sequence of the RBD of SARS-CoV-2 (QHR63250.2), amino acid sequences reflecting representative mutations in SARS-CoV-2 mutant strains (Delta strain, BA1 strain, BA2.75 strain, BA4 / 5 strain) were created and aligned using ClustalW. The binding region of VM793 is shown for the alignment results (Figure 11). VM793, which shows good binding activity to the RBD of the Wuhan strain, Delta strain, BA1 strain, BA2.75 strain, and BA4 / 5 strain, has binding sites in two independent amino acid regions on the RBD (the amino acid region from the 33rd tyrosine to the 43rd cysteine in SEQ ID NO: 1 and the amino acid region from the 124th aspartic acid to the 137th leucine). Among these, no amino acid sequence mutations were observed in the amino acid region from tyrosine at position 33 to cysteine at position 43 of SEQ ID NO: 1, which was thought to be the reason why VM793 maintains its binding activity against various mutant strains of SARS-CoV-2. In addition, in the amino acid region from aspartic acid at position 124 to leucine at position 137 of SEQ ID NO: 1, characteristic amino acid sequence mutations are observed for each mutant strain, but the results of binding activity (Table 3) and neutralizing activity (Table 6) showed that the amino acid mutations observed in this region did not have a significant effect on the binding mode of VM793, and it was thought that the reason why VM793 maintains its binding activity and neutralizing activity against various mutant strains of SARS-CoV-2 is that it has a binding site in this amino acid region.
[0080] The binding region of VM800 is shown for the alignment results (Figure 12). VM800, which shows good binding activity against the Wuhan and Delta strains, has binding sites in two independent amino acid regions on the RBD (the amino acid region from tyrosine at position 51 to phenylalanine at position 56 in SEQ ID NO: 1, and the amino acid region from glycine at position 178 to valine at position 194 in SEQ ID NO: 1). In other words, it was found that VM800 shows a different binding site for RBD than VM793, and this was thought to be the reason why the SARS-CoV-2 neutralizing activity of the VM793-VM800 cocktail is synergistically improved compared to when VM793 or VM800 is used alone.
Claims
1. An anti-SARS-CoV-2 monoclonal antibody that binds to an epitope represented by the following (a) or (b): (a) an epitope contained in a region from tyrosine at position 33 to cysteine at position 43 of the amino acid sequence shown in SEQ ID NO: 1 or an amino acid region equivalent thereto, and an epitope contained in a region from aspartic acid at position 124 to leucine at position 137 of the amino acid sequence shown in SEQ ID NO: 1 or an amino acid region equivalent thereto (b) an epitope contained in the amino acid region from tyrosine at position 51 to phenylalanine at position 56 of the amino acid sequence shown in SEQ ID NO: 1 or an amino acid region equivalent thereto, and an epitope contained in the region from glycine at position 178 to valine at position 194 of the amino acid sequence shown in SEQ ID NO: 1 or an equivalent region thereto
2. The antibody described in claim 1, which binds to the epitope represented by (a) has one or more structural domains including CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 2, CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 3, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO:
4.
3. The antibody described in claim 1, wherein the antibody that binds to the epitope represented by (b) has one or more structural domains including a CDR1 consisting of the amino acid sequence represented by SEQ ID NO:5, a CDR2 consisting of the amino acid sequence represented by SEQ ID NO:6, and a CDR3 consisting of the amino acid sequence represented by SEQ ID NO:
7.
4. The antibody according to any one of claims 1 to 3, which is either a single domain antibody, a single domain antibody multimer comprising at least one of said single domain antibodies, or an antibody in which at least one of said single domain antibodies is linked to another molecule.
5. The antibody of claim 4, wherein the single domain antibody has a humanized character.
6. A nucleic acid encoding the antibody according to any one of claims 1 to 5.
7. A therapeutic agent for SARS-CoV-2 infection, comprising the antibody according to any one of claims 1 to 5.
8. A therapeutic agent for SARS-CoV-2 infection comprising a combination of an antibody that binds to the epitope shown in (a) and an antibody that binds to the epitope shown in (b).
